Non-hodgkin's lymphoma presenting with biliary tract obstruction. A discussion of seven patients and a review of the literature

✍ Scribed by Panos Fidias; Robert W. Carey; Michael L. Grossbard

• Publisher: John Wiley and Sons
• Year: 1995
• Tongue: English
• Weight: 751 KB
• Volume: 75
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19950401)75:7<1669::aid-cncr2820750718>3.0.co;2-3

✦ Synopsis

Background:

Biliary tract obstruction is a rare manifestation of non-hodgkin's lymphoma (nhl). because of the small numbers of patients studied, management of this condition has been inconsistent. most patients have been treated with biliary diversion, and doxorubicin frequently has been withheld from initial therapy.

Methods:

Seven patients with nhl presenting with malignant biliary tract obstruction were identified at the massachusetts general hospital. relevant clinical characteristics, laboratory values, treatment, and outcome are reported for all patients. thirty-eight additional patients were identified through a medline search; and the management and results of the patients reported here are discussed with reference to those patients.

Results:

Biliary tract obstruction was the presenting symptom in 0.8% of the patients with nhl. bilirubin values at presentation ranged from 5.0-23.2 mg/dl. one patient had localized pancreatic lymphoma. four of the seven patients had advanced-stage disease. the tumor was intermediate or high grade in five patients. four patients underwent placement of a biliary stent or drainage catheter. six patients received combination chemotherapy without doxorubicin in the initial cycle. hyperbilirubinemia resolved in all patients within 3 months, regardless of use of a stent. six patients responded to chemotherapy and one patient had progressive disease. two of the six responders died, one with relapsed lymphoma.

Conclusions:

Nhl presenting with biliary tract obstruction can be effectively treated with chemotherapy, with or without a procedure for biliary diversion. the use of doxorubicin in the presence of hyperbilirubinemia secondary to biliary tract obstruction remains controversial, and its omission from the initial cycles of chemotherapy for nhl may not influence outcome.